Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,421 to 1,440 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and optimization of molecular glue compounds that inhibit a noncovalent E2 enzyme-ubiquitin complex. | Sci Adv | 2021 | 34705497 | PubTator, text mining | PubMed |
| Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas. | Curr Treat Options Oncol | 2021 | 34694508 | PubTator, text mining | PubMed |
| T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients. | J Exp Med | 2021 | 34694366 | PubTator, text mining | PubMed |
| A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. | Cells | 2021 | 34685679 | PubTator, text mining | PubMed |
| Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article. | Cancers (Basel) | 2021 | 34680358 | PubTator, text mining | PubMed |
| Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. | Cancers (Basel) | 2021 | 34680303 | PubTator, text mining | PubMed |
| Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q. | Cancers (Basel) | 2021 | 34680233 | PubTator, text mining | PubMed |
| Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. | Cancers (Basel) | 2021 | 34680184 | PubTator, text mining | PubMed |
| Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. | Nat Chem Biol | 2021 | 34675414 | PubTator, text mining | PubMed |
| Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations. | Front Med (Lausanne) | 2021 | 34671620 | PubTator, text mining | PubMed |
| Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins. | J Med Chem | 2021 | 34652918 | PubTator, text mining | PubMed |
| Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design. | J Med Chem | 2021 | 34652145 | PubTator, text mining | PubMed |
| Sirtuin Modulators in Cellular and Animal Models of Human Diseases. | Front Pharmacol | 2021 | 34650436 | PubTator, text mining | PubMed |
| Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors. | Sci Transl Med | 2021 | 34644148 | PubTator, text mining | PubMed |
| Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. | Cancers (Basel) | 2021 | 34638471 | PubTator, text mining | PubMed |
| Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. | Cancers (Basel) | 2021 | 34638353 | PubTator, text mining | PubMed |
| Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. | Cancers (Basel) | 2021 | 34638271 | PubTator, text mining | PubMed |
| A guide to senolytic intervention in neurodegenerative disease. | Mech Ageing Dev | 2021 | 34627838 | PubTator, text mining | PubMed |
| What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments. | Ther Adv Med Oncol | 2021 | 34621332 | PubTator, text mining | PubMed |
| ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment. | Blood Adv | 2021 | 34614505 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=72